Desmoteplase

Bibliography

• Dafer RM, Biller J. Desmoteplase in the treatment of acute ischemic stroke. Expert Rev Neurother 2007;7:333-7
   PubMed Web of Science ®Google Scholar
• Douglas VC, Tong DC, Gillum LA, et al. Do the brain attack Coalition's criteria for stroke centers improve care for ischemic stroke? Neurology 2005;64:422-7
   PubMed Web of Science ®Google Scholar
• The National Institute of Neurological Disorders and Stroke (NINDS) rtPA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7
   PubMed Web of Science ®Google Scholar
• Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-29
   PubMed Web of Science ®Google Scholar
• Arnold AE, Brower RW, Collen D, et al. Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency. European Co-operative Study Groups for rt-PA. J Am Coll Cardiol 1989;14:581-8
   PubMed Web of Science ®Google Scholar
• Bringmann P, Gruber D, Liese A, et al. Structural features mediating fibrin selectivity of vampire bat plasminogen activators. J Biol Chem 1995;270:25596-603
   PubMed Web of Science ®Google Scholar
• Kratzschmar J, Haendler B, Langer G, et al. The plasminogen activator family from the salivary gland of the vampire bat Desmodus rotundus, cloning and expression. Gene 1991;105:229-37
   PubMed Web of Science ®Google Scholar
• Hawkey C. Plasminogen activator in the saliva of the vampire bat Desmodus rotundus. Nature 1966;211:434-5
   PubMed Web of Science ®Google Scholar
• Schleuning WD, Alagon A, Boidol W, et al. Plasminogen activators from the saliva of Desmodus rotundus (common vampire bat): unique fibrin specificity. Ann NY Acad Sci 1992;667:395-403
   PubMed Web of Science ®Google Scholar
• Witt W, Maass B, Baldus B, et al. Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs. Fast and persistent recanalization by intravenous bolus administration. Circulation 1994;90:421-6
   PubMed Web of Science ®Google Scholar
• Schleuning WD. Vampire bat plasminogen activator DSPA-alpha-1 (Desmoteplase): a thrombolytic drug optimized by natural selection. Haemostasis 2001;31:118-22
   PubMedGoogle Scholar
• Petri T, Langer G, Bringmann P, et al. Production of vampire bat plasminogen activator DSPAα1 in CHO and insect cells. J Biotechnol 1995;39:75-83
   PubMed Web of Science ®Google Scholar
• Stewart RJ, Fredenburgh JC, Weitz JI. Characterization of the interactions of plasminogen and tissue and vampire bat plasminogen activators with fibrinogen, fibrin, and the complex of D-dimer noncovalently linked to fragment E. J Biol Chem 1998;273:18292-9
   PubMed Web of Science ®Google Scholar
• Walker JB, Nesheim ME. A kinetic analysis of the tissue plasminogen activator and DSPAα1 cofactor activities of untreated and TAFIa-treated soluble fibrin degradation products of varying size. J Biol Chem 2001;276:3138-48
   PubMed Web of Science ®Google Scholar
• Renatus M, Stubbs MT, Huber R, et al. Catalytic domain structure of vampire bat plasminogen activator: a molecular paradigm for proteolysis without activation cleavage. Biochemistry 1997;36:13483-93
   PubMed Web of Science ®Google Scholar
• Pugsley MK, Lipka L, Petersen KU, Soehngen M. A new hope for stroke? Evidence for the use of rDSPAα1 (Desmoteplase) in acute ischemic stroke. Proc West Pharmacol Soc 2006;49:1-5
   Google Scholar
• Epple G, Schleuning WD, Kettelgerdes G, et al. Prion protein stimulates tissue-type plasminogen activator-mediated plasmin generation via a lysine-binding site on kringle 2. J Thromb Haemost 2004;2:962-8
   PubMed Web of Science ®Google Scholar
• Lopez-Atalaya JP, Roussel BD, Ali C, et al. Recombinant desmodus rotundus salivary plasminogen activator crosses the blood-brain barrier through a low-density lipoprotein receptor-related protein-dependent mechanism without exerting neurotoxic effects. Stroke 2007;38:1036-43
   PubMed Web of Science ®Google Scholar
• Tsirka S, Rogove AD, Strickland S. Neuronal cell death and tPA. Nature 1996;384:123-4
   PubMed Web of Science ®Google Scholar
• Liberatore GT, Samson A, Bladin C, et al. Vampire bat salivary plasminogen activator (Desmoteplase). A unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke 2003;34:537-43
   PubMed Web of Science ®Google Scholar
• Reddrop C, Moldrich RX, Beart PM, et al. Vampire bat salivary plasminogen activator (Desmoteplase) inhibits tissue-type plasminogen activity-induced potential of excitotoxic injury. Stroke 2005;36:1241-6
   PubMed Web of Science ®Google Scholar
• Tebbe U, Bramlage P, Graf A, et al. Desmoteplase in acute massive pulmonary thromboembolism. Thromb Haemost 2009;101:557-62
   PubMed Web of Science ®Google Scholar
• Hacke W, Albers G, Al-Rawi Y, et al. The desmoteplase in acute ischemic stroke trial (DIAS): a Phase II MRI-based 9-hours window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005;36:66-73
   PubMed Web of Science ®Google Scholar
• Furlan AJ, Eyding D, Albers GW, et al. Dose escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006;37:1227-31
   PubMed Web of Science ®Google Scholar
• Hacke W, Furlan AJ, Al-Rawi Y, et al. Intravenous desmoteplase in patients with acute ischemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective randomised, double-blind, placebo-controlled study. Lancet Neurol 2009;8:141-50
   PubMed Web of Science ®Google Scholar
• Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II). Lancet 1998;352:1245-51
   PubMed Web of Science ®Google Scholar
• DIAS-3. Efficacy and safety study of Desmoteplase to treat acute ischemic stroke. The Internet Stroke Center, Stroke Trials Registry, 2009. Available from: http://www.strokecenter.org/trials/trialDetail.aspx?tid=914&search_string=DIAS [Last accessed 26 April 2009]
   Google Scholar
• DIAS-4. Efficacy and Safety study of desmoteplase to treat acute ischemic stroke The Internet Stroke Center, Stroke Trials Registry, 2009. Available from: http://www.strokecenter.org/trials/trialDetail.aspx?tid=961&search_string=DIAS [Last accessed 26 April 2009]
   Google Scholar
• Albers GW, Thijs VN, Wechsler L, et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol 2006;60:508-17
   PubMed Web of Science ®Google Scholar
• Davis SM, Donnan GA, Persons MW, et al. Effects of alteplase beyond 3 h stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomized trial. Lancet Neurol 2008;7:299-309
   PubMed Web of Science ®Google Scholar
• Fieschi C, Argentino C, Lenzi GL, et al. Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours. J Neurol Sci 1989;91:311-21
   PubMed Web of Science ®Google Scholar
• Donnan GA, Baron JC, Davis S. Penumbral selection of patients for trials of acute stroke therapy. Lancet Neurol 2009;8:261-9
   PubMed Web of Science ®Google Scholar